Takeover bid for Arana
Friday, 27 February, 2009
Arana Therapeutics is in discussions with an unnamed party about a possible takeover bid for the cash-rich company.
Arana, itself the result of a merger between Evogenix and Peptech, has a full and promising pipeline and a very strong cash position of $175 million.
It discontinued its age-related macular degeneration project PMX53 recently, but has strong candidates in inflammatory diseases. Lead candidate ART621, an anti-TNF antibody, is nearing the end of a Phase II trial for psoriasis and is beginning Phase II for rheumatoid arthritis.
The company’s market capitalisation is a very healthy $190 million and its finances strong enough to have carried out a share buy-back.
The company said it would make an announcement on both the bid and the search for a new CEO in due course.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
